(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 April 2011 (21.04.2011)

PCT

(10) International Publication Number
WO 2011/045702 A1

(51) International Patent Classification:
C07D 487/04 (2006.01) *A61P 37/00* (2006.01)
A61K 31/519 (2006.01)

(21) International Application Number:
PCT/IB2010/054447

(22) International Filing Date:
1 October 2010 (01.10.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/252,039 15 October 2009 (15.10.2009) US

(71) Applicant *(for all designated States except US)*: **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, New York 10017 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ACKER, Brad Alan** [US/US]; 4233 Millers Ridge Drive, Saint Charles, Missouri 63304 (US). **HARTMANN, Susan J.** [US/US]; 613 West Essex Avenue, Kirkwood, Missouri 63122 (US). **HUANG, Horng-Chih** [US/US]; 1126 Nooning Tree Drive, Chesterfield, Missouri 63017 (US). **JACOBSEN, Eric Jon** [US/US]; 1503 Lace Bark Court, Chesterfield, Missouri 63005 (US). **PROMO, Michele Ann** [US/US]; 239 N. Westover Blvd., Apt. 4122, Albany, Georgia 31707 (US). **WOLFSON, Sergey Gregory** [US/US]; 15599 Hitchcock Road, Chesterfield, Missouri 63017 (US). **XIE, Jin** [US/US]; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017 (US).

(74) Agent: **KLEIMAN, Gabriel**; Pfizer Inc. 235 East 42nd Street, New York, New York 10017 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the identity of the inventor (Rule 4.17(i))*

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*


Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

[Continued on next page]

(54) Title: PYRROLO[2,3-D] PYRIMIDINE COMPOUNDS



(I)

(57) Abstract: Described herein are pyrrolo[2,3-d]pyrimidine compounds, their use as Janus Kinase (JAK) inhibitors, pharmaceutical compositions containing these compounds, and methods for their preparation.

WO 2011/045702 A1

— *with sequence listing part of description (Rule 5.2(a))*